Adding olaparib to first-line treatment with abiraterone extends overall survival in patients with metastatic castration-resistant prostate cancer, a phase 3 study suggests.
Adding niraparib to AAP improves rPFS in patients with BRCA-mutated metastatic castration-resistant prostate cancer, a phase 3 trial suggests.
Intensified ADT with apalutamide, with or without abiraterone plus prednisone, for 52 weeks prolonged PSA progression-free survival compared with ADT alone among men with high-risk biochemically recurrent prostate cancer following radical prostatectomy.
Rucaparib improves radiographic progression-free survival when compared with physician’s choice of therapy in patients with metastatic castration-resistant prostate cancer, according to results from the TRITON3 trial.
Dietary counseling may improve clinical outcomes for men with prostate cancer.
Cytoreductive radical prostatectomy for newly diagnosed metastatic hormone-sensitive prostate cancer can be performed with minimal morbidity and is associated with a low risk for symptomatic local recurrence.
Nephron-sparing management is one strategy to reduce risks, according to investigators.
The higher risk for radiographic progression and death observed among older men taking abiraterone is likely due to more toxicity leading to more frequent and earlier drug discontinuation, according to investigators.
Neoadjuvant chemotherapy prior to radical cystectomy is not associated with an increased risk for major complications vs radical cystectomy alone, but it does increase the risk for bleeding requiring transfusion and sepsis.
Among men with intermediate- and high-risk disease, Black men had significant 22% and 37% lower odds of receiving definitive treatment, respectively, compared with White men, a study found.
Please login or register first to view this content.
